GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Net Cash per Share

NXSCF (Next Science) Net Cash per Share : $0.00 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Next Science's Net Cash per Share for the quarter that ended in Jun. 2024 was $0.00.

The historical rank and industry rank for Next Science's Net Cash per Share or its related term are showing as below:

During the past 6 years, the highest Price-to-Net-Cash Ratio of Next Science was 46.50. The lowest was 17.00. And the median was 17.93.

NXSCF's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.325
* Ranked among companies with meaningful Price-to-Net-Cash only.

Next Science Net Cash per Share Historical Data

The historical data trend for Next Science's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Net Cash per Share Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial 0.08 0.05 0.02 - 0.01

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.03 - -0.04 0.01 -

Competitive Comparison of Next Science's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Next Science's Price-to-Net-Cash falls into.



Next Science Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Next Science's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(9.277-5.079-0)/291.695
=0.01

Next Science's Net Cash per Share for the quarter that ended in Jun. 2024 is calculated as

Net Cash per Share (Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(3.609-4.757-0)/291.695
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Next Science  (OTCPK:NXSCF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Next Science Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Next Science's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science Business Description

Traded in Other Exchanges
Address
264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

Next Science Headlines

From GuruFocus

Next Science Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Next Science Ltd Ordinary Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Next Science Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Full Year 2022 Next Science Ltd Earnings Call Transcript

By GuruFocus Research 02-14-2024

Half Year 2021 Next Science Ltd Earnings Call Transcript

By GuruFocus Research 02-14-2024

Full Year 2020 Next Science Ltd Earnings Call Transcript

By GuruFocus Research 02-14-2024

Half Year 2022 Next Science Ltd Earnings Call Transcript

By GuruFocus Research 02-14-2024

Next Science to Exhibit Surgical Product Portfolio at AAOS 2021

By Business Wire Business Wire 08-24-2021